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Background:  The use of antithrombotics in atrial fibrillation (AF) varies according to geography, physician specialty, and type of AF. We sought to 
determine real life use of these agents compared with current guidelines.
Methods:  The RealiseAF registry includes 10,546 patients from 831 sites in 26 countries on 4 continents (Africa, Asia, Europe, South America), 
with at least one documented AF episode in the last 12 months. Participating physicians were randomly selected and were office- or hospital-
based cardiologists and internists. Patient information included baseline characteristics, symptoms, ECG data, medical history, risk factors, AF 
characteristics and management (rate vs rhythm control), and medications (antithrombotics, antiarrhythmic drugs, and/or rate control agents). 
Primary analyses included frequency of AF control (achievement of sinus rhythm or AF with resting heart rate ≤ 80 bpm) and description of 
cardiovascular risk. Mean age was 66.6 ±12.2 years, 56.4% were male. AF was paroxysmal in 24.8%, persistent in 22.3%, and permanent in 46.4% 
of patients.
Results:  The percentage of patients receiving vitamin K antagonists and antiplatelet treatment based on CHADS2 score is shown.
Conclusions:  These results from a broad geographic sample confirm that AF management in a real life setting deviates from guidelines 
recommendations with both overuse and underuse of antithrombotics in ~50% of patients. These findings emphasize the continuous need for 
medical education and information.
